Treatment and management of ascites and hepatorenal syndrome: an update

Ascites and renal dysfunction are frequent complications experienced by patients with cirrhosis of the liver. Ascites is the pathologic accumulation of fluid in the peritoneal cavity, and is one of the cardinal signs of portal hypertension. The diagnostic evaluation of ascites involves assessment of...

Full description

Bibliographic Details
Main Authors: Kurt Lenz, Robert Buder, Lisbeth Kapun, Martin Voglmayr
Format: Article
Language:English
Published: SAGE Publishing 2015-03-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756283X14564673
_version_ 1818554486869721088
author Kurt Lenz
Robert Buder
Lisbeth Kapun
Martin Voglmayr
author_facet Kurt Lenz
Robert Buder
Lisbeth Kapun
Martin Voglmayr
author_sort Kurt Lenz
collection DOAJ
description Ascites and renal dysfunction are frequent complications experienced by patients with cirrhosis of the liver. Ascites is the pathologic accumulation of fluid in the peritoneal cavity, and is one of the cardinal signs of portal hypertension. The diagnostic evaluation of ascites involves assessment of its granulocyte count and protein concentration to exclude complications such as infection or malignoma and to allow risk stratification for the development of spontaneous peritonitis. Although sodium restriction and diuretics remain the cornerstone of the management of ascites, many patients require additional therapy when they become refractory to this treatment. In this situation, the treatment of choice is repeated large-volume paracentesis. Alteration in splanchnic hemodynamics is one of the most important changes underlying the development of ascites. Further splanchnic dilation leads to changes in systemic hemodynamics, activating vasopressor agents and leading to decreased renal perfusion. Small alterations in renal function influence the prognosis, which depends on the cause of renal failure. Prerenal failure is evident in about 70% of patients, whereas in about 30% of patients the cause is hepatorenal syndrome (HRS), which is associated with a worse prognosis. Therefore, effective therapy is of great clinical importance. Recent data indicate that use of the new definition of acute kidney injury facilitates the identification and treatment of patients with renal insufficiency more rapidly than use of the current criteria for HRS. In this review article, we evaluate approaches to the management of patients with ascites and HRS.
first_indexed 2024-12-12T09:40:19Z
format Article
id doaj.art-2e62db0f1de6489c9c881b8bf9c9b46f
institution Directory Open Access Journal
issn 1756-283X
1756-2848
language English
last_indexed 2024-12-12T09:40:19Z
publishDate 2015-03-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Gastroenterology
spelling doaj.art-2e62db0f1de6489c9c881b8bf9c9b46f2022-12-22T00:28:34ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X1756-28482015-03-01810.1177/1756283X14564673Treatment and management of ascites and hepatorenal syndrome: an updateKurt LenzRobert BuderLisbeth KapunMartin VoglmayrAscites and renal dysfunction are frequent complications experienced by patients with cirrhosis of the liver. Ascites is the pathologic accumulation of fluid in the peritoneal cavity, and is one of the cardinal signs of portal hypertension. The diagnostic evaluation of ascites involves assessment of its granulocyte count and protein concentration to exclude complications such as infection or malignoma and to allow risk stratification for the development of spontaneous peritonitis. Although sodium restriction and diuretics remain the cornerstone of the management of ascites, many patients require additional therapy when they become refractory to this treatment. In this situation, the treatment of choice is repeated large-volume paracentesis. Alteration in splanchnic hemodynamics is one of the most important changes underlying the development of ascites. Further splanchnic dilation leads to changes in systemic hemodynamics, activating vasopressor agents and leading to decreased renal perfusion. Small alterations in renal function influence the prognosis, which depends on the cause of renal failure. Prerenal failure is evident in about 70% of patients, whereas in about 30% of patients the cause is hepatorenal syndrome (HRS), which is associated with a worse prognosis. Therefore, effective therapy is of great clinical importance. Recent data indicate that use of the new definition of acute kidney injury facilitates the identification and treatment of patients with renal insufficiency more rapidly than use of the current criteria for HRS. In this review article, we evaluate approaches to the management of patients with ascites and HRS.https://doi.org/10.1177/1756283X14564673
spellingShingle Kurt Lenz
Robert Buder
Lisbeth Kapun
Martin Voglmayr
Treatment and management of ascites and hepatorenal syndrome: an update
Therapeutic Advances in Gastroenterology
title Treatment and management of ascites and hepatorenal syndrome: an update
title_full Treatment and management of ascites and hepatorenal syndrome: an update
title_fullStr Treatment and management of ascites and hepatorenal syndrome: an update
title_full_unstemmed Treatment and management of ascites and hepatorenal syndrome: an update
title_short Treatment and management of ascites and hepatorenal syndrome: an update
title_sort treatment and management of ascites and hepatorenal syndrome an update
url https://doi.org/10.1177/1756283X14564673
work_keys_str_mv AT kurtlenz treatmentandmanagementofascitesandhepatorenalsyndromeanupdate
AT robertbuder treatmentandmanagementofascitesandhepatorenalsyndromeanupdate
AT lisbethkapun treatmentandmanagementofascitesandhepatorenalsyndromeanupdate
AT martinvoglmayr treatmentandmanagementofascitesandhepatorenalsyndromeanupdate